Death in the fetal, perinatal, and early infant age-group has a multitude of causes, a proportion of which is presumed to be genetic. Defining a specific genetic aberration leading to the death is problematic at this young age, due to limited phenotypegenotype correlation inherent in the underdeveloped phenotype, the inability to assess certain phenotypic traits after death, and the problems of dealing with rare disorders. In this study, our aim was to increase the yield of identification of a defined genetic cause of an early death. Therefore, we employed whole genome sequencing and bioinformatic filtering techniques as a comprehensive, unbiased genetic investigation into 16 fetal, perinatal, and early infant deaths, which had undergone a full autopsy. A likely genetic cause was identified in two cases (in genes; COL2A1 and RYR1) and a speculative genetic cause in a further six cases (in genes: ARHGAP35, BBS7, CASZ1, CRIM1, DHCR7, HADHB, HAPLN3, HSPG2, MYO18B, and SRGAP2). This investigation indicates that whole genome sequencing is a significantly enabling technology when determining genetic causes of early death.
Introduction
Death during the fetal, perinatal, and early infant period has many causes, including complex developmental abnormalities incompatible with prolonged postpartum life. Many of these major developmental abnormalities are believed to occur as a result of inherited or de novo genetic aberrations. Nonetheless, in many instances, a genetic cause for the abnormal phenotype cannot be ascertained, which negatively impacts risk assessment for future pregnancies, as well as affecting closure for the bereaved parents.
We describe the use of clinical whole genome sequencing (WGS) to enhance the diagnostic capability in the context of fetal, perinatal, and early infant death. Our heterogeneous cohort consisted of 16 probands on male probands were filtered at < 1% in the same population databases.
Variants of interest were analyzed further using two complementary approaches: First, variants were filtered against curated lists of genes currently known to be associated with the phenotype (see Supplementary Data 2) . When more than one gene list was relevant for a proband phenotype, simultaneous interrogation of the lists was performed. Sanger sequencing was used to confirm the validity of all variants thought likely to be causative for the phenotype. Second, variants were assessed in the absence of these gene lists, via our in-house, CohortLevel Variant Analysis. Here, all protein affecting variants with a population frequency < 1%, a Combined Annotation-Dependent Depletion score ! 20 (see Supplementary Data 1) and that were not found in nonfamily members of the in-house cohort, were analyzed further. The overall algorithm of investigation is depicted graphically in Supplementary Data 3.
Classification and interpretation of variants were based on the American College of Medical Genetics and Genomics (ACMG) standards and guidelines, 6 current knowledge, and linkage to the clinical phenotype.
The study was a retrospective study and approved by the Human Research Ethics Committee of Mater Health, Brisbane, Queensland, Australia (HREC/14/ MHS/74). Appropriate parental consent was obtained in all cases.
Results
The WGS data analyzed were from 16 families, with 14 of these represented by a trio (the proband and biological parents) and 2 families represented by a trio and one or more siblings. Listed in Table 1 is the phenotype associated with fetal, perinatal, or early infant death (after full autopsy examination). These cases were selected since the phenotype was thought potentially to include a genetic cause in the proband.
On average, 97% of the genome was called for both alleles for the 16 probands and the minimum coverage was 80 times (CG variant calling depends on an algorithmic interpretation of depth and distribution of coverage together with other quality criteria 1 ). Each genome had an average of 4.3 million variants called, which included an average of 20,796 coding variants.
Bioinformatics Filtering by Phenotype Curated Gene Lists
By filtering genes through our curated phenotype gene lists, variants thought likely to have contributed to the death were detected in 2 of the 16 cases (12.5%; Families 1 and 13). Family 1. The neonatal death occurred in a premature infant at 2 h of age and was due to pulmonary hypoplasia secondary to arthrogryposis. The proband, and his similarly affected sibling, had Sanger sequence-confirmed compound heterozygous variants in RYR1 (ryanodine receptor 1, OMIM*180901). The variants were a paternally inherited splice site variant, assessed as pathogenic and a maternally inherited missense variant assessed as likely pathogenic (Table 2 ). These novel variants had not been reported previously in either population control databases or clinically affected patients, and were not seen in any other samples within our in-house cohort. Pathogenic variants in the RYR1 gene are associated with a variety of congenital myopathies. The original autopsy findings indicated a global deficiency in muscle fibers, with Type 1 fiber predominance (Figure 1 ), a finding which is not specific as to etiology, but consistent with RYR1-associated congenital myopathy. Hence, the cause of perinatal death was determined to be RYR1-associated congenital myopathy, with an autosomal compound heterozygous-recessive MOI.
Family 13. The neonatal death occurred in a premature infant at 32 h of age and was due to respiratory distress secondary to Pierre Robin sequence (micrognathia, glossoptosis, cleft soft palate) in a neonate with skeletal dysplasia, consistent with Kniest dysplasia (an autosomal dominantly inherited skeletal dysplasia). A heterozygous, de novo, likely pathogenic, spice site variant in the COL2A1 gene was detected in the proband's sample (Table 2 ). This variant was confirmed by Sanger sequencing, had been identified by a skeletal dysplasia-targeted gene panel during autopsy work-up (Table 1 ) and has been previously described in a patient with Kniest dysplasia. This variant alters part of the consensus splice donor site, which is predicted to affect mRNA splicing, although this has not been confirmed experimentally. 7 This variant was not detected in population databases or in our in-house database. The combination of Kniest dysplasia and Pierre Robin sequence, while rare, has been previously reported. 8 Other variants of interest for potential involvement in the proband phenotype were identified in probands for Families 3, 8, and 15. These were defined as speculative for a number of reasons, as follows:
Family 3. This fetal death occurred at 24 weeks gestation. Autopsy revealed arthrogryposis, severe growth restriction, simple external ears, micrognathia, left mandible deformity, asymmetric facial bones, a bi-lobed right lung, and a single umbilical artery (Table 1) . Histopathological examination of the skeletal muscle samples showed amyoplasia (ie, fat replacement), increased endomysial connective tissue and perimysial fibrosis, findings which are effectively endstage and nonspecific as to etiology.
This proband inherited compound heterozygous variants in two separate genes (HSPG2, heparan sulfate proteoglycan 2, OMIM#142461; and MYO18B, myosin XVIIIB, OMIM#607295). The phenotypes associated with mutations in both of these genes potentially overlapped with the phenotype documented in this fetus. The HSPG2 gene within the proband included a paternally inherited missense variant of unknown significance and a maternally inherited missense variant assessed as likely benign (Table 2 ). Both variants were noted to be within putative glycosylation sites of the encoded, heavily glycosylated protein (data not shown), both were present in population databases at low frequency, and neither variant was found in other samples within our in-house database.
HSPG2 encodes perlecan, a large multi-domain proteoglycan that binds and cross-links extracellular matrix (ECM) components and cell-surface molecules. Perlecan has multiple proposed functions, including growth factor signaling, cell adhesion, angiogenesis and basement membrane, and cartilage maintenance. Pathogenic variants in the HSPG2 gene are associated with Schwartz-Jampel syndrome (SJS) Type 1 (SJS1; OMIM *255800). SJS1 can be of autosomal-dominant or -recessive inheritance and in its most severe form (Type 1B) can manifest in utero. 9, 10 The SJS phenotype has overlap with the proband phenotype and includes dysmorphic facies, micrognathia, abnormal external ears, short stature, and an abnormal axial and appendageal skeleton. Perlecan is associated with endochondral ossification and normally is found localized to the ECM of the hypertrophic and proliferative zones of growth plate cartilage. Loss of ECM localization with perinuclear cytoplasmic retention has been observed in SJS patients. 11 Murine models of SJS indicate abnormal development of the hypertrophic zones of cartilaginous growth plates. 12 The discovery of variants of interest in the HSPG2 gene in this proband induced us to further investigate the proband's autopsy tissues. This revealed expansion of the hypertrophic zone of rib cartilage, with enlarged and disorganized chondrocytes (Figure 2(A) to (C) ). Furthermore, immunohistochemistry showed aberrant perlecan expression, with the perlecan confined to the perinuclear chondrocytic cytoplasm and no detectable perlecan present in the extracellular cartilaginous matrix (Figure 2(D) to (F) ). These phenotypic findings are compatible with abnormal perlecan expression consequent on the HSPG2 variants identified. However, despite compound heterozygous variants in this gene, the potential of these variants to disrupt glycosylation sites within this proteoglycan, similarities between the proband phenotype and those documented in both human SJS patients and murine models of SJS and the demonstration of aberrant perlecan expression, these variants were listed as speculatively causative of the proband disease, based on ACGM standards and guidelines.
In addition to the HSPG2 variants, compound heterozygous inheritance of variants in the MYO18B gene was also identified. These variants were a paternally inherited splice site variant of unknown significance and a maternally inherited missense variant (likely benign; Table 2 ). Mutations in this gene have been associated with a poorly defined, rare, inherited myopathy in humans 13 and with the ''frozen'', ie, immotile, mutant in zebrafish.
14 Further Certain variants of speculative significance were detected in genes which are not currently known to be Mendelian disease genes (ie, genes of uncertain significance). As such, they cannot formally be classified according to ACMG criteria. 6 Rather, these genes were assessed for the likelihood that the detected variant has a deleterious effect on the gene product, rather than pathogenicity of the variant with respect to the clinical presentation of the proband.
investigation of the potential contribution of the variant in this gene to the phenotype would necessitate ultrastructural examination of the fetal muscle, together with functional animal studies. However, these modalities were not available in this case.
Family 8. A termination of pregnancy was performed at 20 weeks gestation due to antenatal-detected bilateral renal cystic dysplasia, confirmed at autopsy. This proband was found to have a de novo heterozygous missense variant, assessed as unknown significance, in DHCR7 (7-dehydrocholesterol reductase, OMIM*602858; Table 2 ). Pathogenic variants in the DHCR7 gene cause a deficiency in the enzyme, which leads to Smith-Lemli-Opitz syndrome (SLOS). This is a relatively common disorder of cholesterol synthesis, which results in abnormal functioning of the Hedgehog signaling pathway. SLOS is associated with multiple developmental anomalies, including genitourinary anomalies, with renal cystic dysplasia previously described. 15 While the variant detected in the proband was novel, there have been other missense variants reported at the same position and with the same resulting amino acid change described in patients with SLOS. 16, 17 However, SLOS is an autosomal-recessive condition and no second variant of interest was detected in this gene, nor was there evidence of copy number variation within this region of the genome. It is, however, possible to speculate that while multi-organ developmental abnormalities classical of SLOS are caused by biallelic mutations in DHCR7, heterozygous missense mutations in the same gene may be responsible for nonsyndromic congenital anomalies of the kidney and urinary tract. This has been documented with heterozygous mutation in FRAS1 and FREM2 (whereas biallelic mutations in these same genes cause the multi-organ condition of Fraser syndrome 18 ). Nonetheless, given current evidence indicates that DHCR7-associated disease occurs as a recessive disorder, the finding of the DHCR7 variant as causative of the phenotype remained speculative.
Family 15. The proband was born prematurely and suffered a neonatal death at 5 min of age secondary to idiopathic hydrops. A retrospective diagnosis of mitochondrial trifunctional protein deficiency (MTPD) was made, based on subsequent metabolic studies performed on a similarly affected sibling. A paternally inherited, likely pathogenic splice site variant was identified in the proband in HADHB (hydroxyacyl-CoA dehydrogenase/3-ketoacyl-CoA thiolase/enoylCoA hydratase, beta subunit, OMIM#14340; Table 2 ). This gene is one of the two genes associated with MTPD and the identified variant has been previously described where mRNA sequencing showed skipping of exon 5, which results in an in-frame deletion. 19 . However, MTPD is documented to be an autosomal-recessive condition and no second deleterious variant was found in HADHB by WGS. Copy number variation was not detected in this region by SNP array and no deleterious variant was identified in HADHA, the other gene involved in MTPD. For these reasons, the finding of the HADHB variant as causative of the phenotype remained speculative.
Nonphenotype List-directed Analysis
We are aware that genetic causes of early death are often poorly documented and a substantial number of early deaths are due to rare disorders, with incomplete genetic and phenotypic profiles. For that reason, we determined whether we could identify possible genetic causes of early death beyond those genes curated on to our phenotype lists. This approach was performed on a small number of families where no variants of interest had been found by the curated gene list approach. Nonphenotype-directed analysis was performed on two families where the proband had congenital heart disease (CHD, Families 2 and 7) and one family (Family 16) in which the proband had limb-body wall complex (LBWC)/pentalogy of Cantrell, with which, to date, few genes have been associated. Variants classified as de novo heterozygous, compound heterozygous or homozygous were analyzed. The de novo heterozygous or compound heterozygous variants of interest were investigated as to potential association with the proband phenotype, by scrutinizing the literature on these genes, in both human and nonhuman models of disease. No homozygous variants of interest were identified. Formal ACMG classification as to pathogenicity of many of these variants could not be assessed, since these genes had not previously been associated with human disease.
Family 2. The proband (a term neonate) died with a partially corrected complex, nonsyndromic CHD (ie, partial transposition of the great vessels, partial double outlet right ventricle, ventricular septal defect (VSD) and coarctation of the aorta; Table 1 ). A de novo missense variant was identified in CASZ1 (castor zinc finger protein 1, OMIM#609895), which altered a highly conserved amino acid (Table 2) . CASZ1 encodes the zinc finger transcription factor CASTOR, which interacts directly with CHD5 protein. The CHD5-CASZ1 interaction has been shown to be necessary for cardiac morphogenesis in nonhuman vertebrates (mice and frogs). 20 Further, a heterozygous pathogenic variant in CASZ1 previously has been associated with familial cardiac disease in an autosomal-dominant manner. 21 Family 7. This premature neonate died from a complex CHD (pulmonary stenosis, VSD, over-riding aorta) and was syndromic, with skeletal abnormalities (bilateral tibial hemimelia, clinodactyly, and fifth finger phalangeal hypoplasia; Table 1 ). A de novo, missense variant of unknown significance in BBS7 (Bardet-Biedl syndrome 7, OMIM#607590) was identified ( Table 2 ). BBS7 plays a role in the motility of cilia, which are involved in the looping of the developing heart. Pathogenic variants in BBS7 are known to associate with CHD in the context of Bardet-Biedl syndrome, an autosomal-recessive ciliopathy caused by pathogenic variants in one or more of the many BBS genes. Mutated alleles at more than one BBS gene locus, as well as at those encoding interacting proteins may be required for clinical manifestation of some forms of BBS. However, we did not find any further potentially pathogenic variants in genes associated with BBS, nor major copy number change in this genomic region. 22, 23 This proband was also compound heterozygous for variants in SRGAP2 (Slit-Robo Rho GTPase activating protein 2, OMIM#606524; Table 2 ). In silico analysis of the paternally inherited nonsense variant indicated that it is likely to produce a premature STOP codon three amino acids away from the normal STOP codon. The maternally inherited variant was a splice site variant. SRGAP2 is a downstream component of Slit/Robo signaling. The Slit family of secreted ligands interact with Robo receptors to control guidance for cell types as diverse as neurons and endothelial cells. A Slit/miR-218/Robo regulatory loop is also required during heart tube formation in zebrafish. 24 Reduced SRGAP protein levels are associated with increased cellular migration in normal development. 25 However, functional studies of these variants would be necessary to assess further their potential pathogenicity.
Family 16. The proband of Family 16 had findings consistent with the overlapping phenotypes of LBWC and pentalogy of Cantrell (ie, a large thoraco-abdominal wall and anterior diaphragmatic defect with extra-corporal viscera including the heart, liver, and spleen; severe left upper limb hypoplasia and marked vertebral scoliosis). The proband had de novo variants in three genes ( Table 2) : The missense variant in AHRGAP35 (encoding the glucocorticoid receptor DNAbinding factor 1/GRLF1, OMIM#605277) was absent from all population databases and altered a highly conserved amino acid. GRLF1 is involved in the control of capillary network formation via the VEGF receptor VEGFR2. 26 Additionally, AHRGAP35 is involved in the 19q13.32 microdeletion syndrome, a disorder characterized by abnormalities in the heart, central nervous system, and multiple other regions of the body. 27 The second missense variant in this proband was in CRIM1 (cysteine-rich motor neuron protein 1, OMIM#606189). This variant was not present in any of the three population databases and altered a highly conserved amino acid. CRIM1 is essential for normal embryonic development and binds several growth factors, including Vascular Endothelial Growth Factors (VEGFs), Bone Morphogenic Proteins (BMPs), Platelet Derived Growth Factors (PDGFs), and transforming growth factor b, thus playing a role in a wide range of cell types during embryogenesis. 28 It is essential for murine placental development 29 and in the development of several organs, including the heart. 30 Importantly, it is known to impact the phenotype when haploinsufficient. 31 A further missense variant was identified, in HAPLN3 (hyaluronan and proteoglycan-binding link protein 3), which was absent in all population databases and altered a highly conserved amino acid. HAPLN3 is one of a family of four HAPLNs that influence the ECM, affecting the architecture and function of many tissues in vertebrates. 32 HAPLN3 is implicated in angiogenesis and cardiogenesis. It is reported as expressed in the ECM of the developing heart 33 and is known to be vital for cardiogenesis in Xenopus models, probably by contributing to the maintenance of the hyaluronan matrix in the heart anlage. 34 Further, in rats, Hapln3 and versican are both upregulated by PDGF, suggesting a role in the development of vascular smooth muscle cells. 35 There are several theories relating to the pathogenesis LBWC, one of which is vascular disruption early in gestation (4-6 weeks postfertilization).
36 GRLF1, CRIM1, and HAPLN3 are involved in angiogenesis and/or cardiogenesis. Therefore, it is possible that the variants within the corresponding genes contributed, possibly synergistically, to abnormal function of the angiogenesis pathway, resulting in vascular disruption early in gestation. As would be expected with de novo inheritance, none of these three variants was present in the two healthy siblings of this proband.
This proband also had confined placental mosaicism, involving a ring chromosome 16. Finally, a paternally inherited 1q21.1 deletion, incorporating the TAR locus (thrombocytopaenia-absent radius syndrome, OMIM# 274000) was detected by routine postmortem SNP microarray analysis. TAR syndrome is an autosomal-recessive condition arising when the deletion occurs in trans with a mutation in the RBM8A gene. No mutation was detected in RBM8A in this patient and the proband's phenotype was not that of TAR syndrome. Hence, this deletion was assessed as incidental to the phenotype.
Discussion
Fetal, neonatal, and early infant deaths occur due to a multitude of causes ranging from predominantly environmental through to predominantly genetic. Genetic etiology is attributed to a proportion of macroscopically identifiable structural anomalies, which lead to early death, such as a subset of skeletal dysplasias (eg, FGFR3 mutation and thanatophoric dysplasia). More recently, genetic etiology has been attributed to a subset of early deaths when no macroscopic abnormality can be detected, but where the hitherto unexplained death is associated with variants in long QT syndromesusceptibility genes, 37 presumably causing fatal cardiac arrhythmias. Nonetheless, while the majority of early deaths can be classified by mechanism, a genetic etiology is not elucidated in the majority of cases, leading to inadequate risk assessment for the early death of future offspring.
WGS has the advantage over sequential, individual gene, targeted gene panel, and clinical exome approaches to mutation detection, since it is not confined to a predetermined set of genes associated, at the time of the investigation, with a specific phenotype. This unbiased approach is particularly important when investigating early death, since the phenotype may not be fully developed, due to the young age of the patient and the fact that minimal investigations may have been achieved during intrauterine or postnatal life, negating access to biochemical, behavioral or functional data. Additionally, at this early age, a single phenotypic finding could potentially be due to several disparate causes (eg, fetal growth restriction due to placental insufficiency or skeletal dysplasia, as seen in the proband of Family 4), necessitating investigation via multiple diagnostic gene panels, if indeed appropriate panels exist.
In this study, we chose to use WGS as opposed to whole exome sequencing (WES) as a platform for analysis, due to a number of advantages of WGS over WES: Given that the reproductive lifespan of the bereaved parents may extend to several subsequent decades, a complete genomic record of the deceased, including the noncoding regions, facilitates future evaluation of areas of the genome not diagnostically evaluable at the time of the death. Further, currently WGS typically gives more coverage over a higher percentage of protein-coding regions than WES; WGS, but not WES, is able to capture variants in splice acceptor and donor sites and WGS captures all isoforms of known genes. All these advantages were deemed particularly relevant to the investigation of fetal, perinatal, and early infant death.
To our knowledge, we are the first to apply WGS as a supplement to diagnostic autopsy in the interrogation of intrauterine, neonatal, and early infant death. In our cohort of 16 probands, with disparate phenotypes, we were able to detect variants with likely functional effect relevant to the mechanism of death in two of these 16 cases. Using various bioinformatic interrogation procedures applied to subsets of the cohort, variants with speculative association with the cause of the death were identified in six further probands (in total, 50% of the cohort). For comparison, two recent studies of infants admitted to neonatal/pediatric intensive care units, highly selected for probable genetic or metabolic conditions, found a genetic cause of the condition by genomic analysis at a rate of 57% and 40%, respectively. 38, 39 Recently, the validity of postmortem genomic investigation was demonstrated by a study using WES on 161 sudden infant death syndrome cases. Here, potentially causative variants were found in 20% cases when the analytical focus was limited to 192 genes associated with cardiovascular and metabolic disease. 40 Our study illustrates a new approach to diagnostic genetic investigations utilizing genomic technologies, as described by Hennekam and Biesecker, 2012 , 41 which can be nominated ''deep phenotyping.'' Before WGS technology, a phenotype would prompt sequential genetic investigation, an approach particularly problematic in early deaths due to the limited specificity of the phenotype. In contrast, WGS leads to a surfeit of genetic information, which can be filtered to some extent via bioinformatics processes. At that point, as in our study, it is necessary to perform focused ancillary assessment of any phenotypic traits linked with the genotype, beyond that which would occur by conventional autopsy, effectively ''deep phenotyping'' based on the gene of interest identified by the genomic analysis. Hence, review of the histopathology of the myopathy detected in the proband in Family 1, together with literature-based investigation as to the presentation of RYR1-associated congenital myopathy in the second trimester of pregnancy, led to a clinically acceptable diagnosis of RYR1-associated myopathy. A further example of ''deep phenotyping,'' without which a diagnosis would not be possible, is illustrated in Family 3, where compound heterozygous inheritance of variants in HSPG2 was identified. ''Deep phenotyping'' revealed abnormal growth plates and aberrant perlecan localization, as documented in humans with SJS secondary to mutations in this gene as well as in mouse models of SJS. 10 . Thus, these specific phenotypic findings indicated that the inherited HSPG2 variant(s) likely contributed to the phenotype. Nonetheless, effective ''deep phenotyping'' necessitates collaborative input from multiple medical and scientific disciplines, including those of the anatomical and molecular pathologists, genetic scientists, bioinformaticians, and clinical geneticists, perhaps best coordinated through institutional molecular review boards.
There are limitations to detecting genetic causes of perinatal death based on WGS as described herein. Several probands were found to have variants of interest in only one allele of a gene associated with a recessive disorder. While we performed SNP microarray analysis on all cases, the technologies used were unable to identify small copy number changes, to an exonic level, which may have occurred in trans with the detected variant. Hence, it is possible that some compound heterozygous aberrations (ie, caused by nucleotide variations and copy number change) were not detected in this cohort.
Overall, our WGS analysis of fetal, neonatal, and early infant death identified variants of likely or speculative interest with regard to the phenotype in 50% of probands, via various methods of interrogation (curated phenotype-derived gene lists, nonphenotype-directed and limited interrogation of noncoding regions). While confirmation of their direct involvement with the phenotype which led to early death was beyond the scope of this study in all cases, the frequency with which such variants were identified by WGS highlights that this approach is likely to be a fruitful mode of investigation into this poorly understood area of medicine.
